ReviewPituitary2012
Pregnancy and acromegaly: a review.
Review in Pituitary, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.
- Acromegaly and pregnancy: a systematic review and meta-analysis.Pituitary · 2022Pooled it
- Management and safety of somatostatin receptor ligands and pegvisomant in pregnant women with acromegaly: a narrative review of the literature.Endocrine · 2026Review
- Safe Continuation of Pegvisomant During Pregnancy in a Patient With Fibrous Dysplasia/McCune-Albright Syndrome.JCEM case reports · 2025Article
- Pregnancy and acromegaly: clinical outcomes of retrospectively analysed data from the German acromegaly registry.Reproductive biology and endocrinology : RB&E · 2024Article
- Approach of Acromegaly during Pregnancy.Diagnostics (Basel, Switzerland) · 2022Review
- First-generation somatostatin receptor ligands and pregnancy: lesson from women with acromegaly.Endocrine · 2020Review
- Octreotide use for rescue of vision in a pregnant patient with acromegaly.Endocrinology, diabetes & metabolism case reports · 2019Article
- Changes in biochemical tests in pregnancy and their clinical significance.Obstetric medicine · 2018Review
- How does pregnancy affect the patients with pituitary adenomas: a study on 113 pregnancies from Turkey.Journal of endocrinological investigation · 2018Article
- Pegvisomant in acromegaly: an update.Journal of endocrinological investigation · 2017Review
- Pregnancy and acromegaly.Pituitary · 2017Review
- General health status and intelligence scores of children of mothers with acromegaly do not differ from those of healthy mothers.Pituitary · 2016Article
- Preconception counselling for women with acromegaly: More questions than answers.Obstetric medicine · 2016Review
- Pregnancy in acromegaly.Therapeutic advances in endocrinology and metabolism · 2015Review
- Article
- Pregnancy in acromegaly patients treated with pegvisomant.Endocrine · 2015Article
- Pituitary tumors and pregnancy: the interplay between a pathologic condition and a physiologic status.Journal of endocrinological investigation · 2014Review
- Estrogen treatment for acromegaly.Pituitary · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To review the literature regarding the diagnosis and management of acromegaly during pregnancy. A systematic literature search was performed using MEDLINE including hand-searching reference lists from original articles. The diagnosis of acromegaly during pregnancy is made difficult due to the physiologic changes in pituitary GH secretion and IGF-1 production resulting from placental GH secretion and the inability of commercial assays to discriminate between pituitary and placental GH. Most patients with acromegaly during pregnancy do not have an increase in tumor size, metabolic complications are uncommon, and neonatal outcome is largely unaffected. IGF-1 levels tend to be stable in such patients possibly due to the high estrogen levels causing GH resistance. Dopamine agonists, somatostatin analogues, and a GH receptor antagonist have been reported to be safe during pregnancy. Patients with visual field defects should be considered for surgery, but in most cases this can be safely postponed until after delivery. Overall, pregnancy in acromegaly is uneventful and newborns unaffected. Dopamine agonists and somatostatin analogues have not been associated with major adverse effects to the fetus; however, more data are needed to validate their safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.